⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

AVTX News

Avalo Therapeutics, Inc. Common Stock

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa